Exosome Sciences (ESI) develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive “liquid biopsies”. Furthermore, the discovery of disease-specific exosomes will provide disease origin insight necessary to enable personalized clinical management. Our research programs are led by exosome industry pioneers.

Learn more about the science behind the technology

Executive Interview with James Joyce CEO
Search engine friendly content

Learn about exosomes and their crucial role in disease development and diagnosis.

Exosome Sciences is actively seeking to extend its reach through collaborations with key partners.
Click here to learn more

To support the therapeutic advances of Aethlon Medical to eliminate disease-enhancing exosomes from circulation, researchers needed to create a highly sensitive diagnostic tool that was able to isolate a broad-spectrum of disease-related exosomes. The result was ELLSA™...
Click for more

September 26, 2014:Aethlon Medical, Inc., and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals...
Click for more